Investor MPM BioVentures IV QP LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by MPM BioVentures IV QP LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2021-02-12 13G/A US16706W1027 / Chiasma Inc 7,154,747 7,167,747
2021-02-12 13G/A SNDX / Syndax Pharmaceuticals, Inc. 2,242,658 0
2020-02-05 13G/A CNAT / Conatus Pharmaceuticals Inc. 2,497,027 0
2020-02-05 13G/A US16706W1027 / Chiasma Inc 7,141,747 7,154,747
2019-02-12 13G/A SNDX / Syndax Pharmaceuticals, Inc. 2,198,755 2,242,658
2019-02-12 13G/A US16706W1027 / Chiasma Inc 7,128,747 7,141,747
2018-02-06 13G CNAT / Conatus Pharmaceuticals Inc. 1,224,300 2,497,027
2018-02-02 13G/A US16706W1027 / Chiasma Inc 7,118,747 7,128,747
2018-02-02 13G/A SNDX / Syndax Pharmaceuticals, Inc. 2,184,301 2,198,755
2017-02-09 13G SNDX / Syndax Pharmaceuticals, Inc. 2,184,301
2017-02-09 13G/A CNAT / Conatus Pharmaceuticals Inc. 1,244,300 1,224,300
2016-02-10 13G US16706W1027 / Chiasma Inc 7,118,747
2016-02-10 13G/A CNAT / Conatus Pharmaceuticals Inc. 1,244,300
2016-02-10 13G/A EPZM / Epizyme Inc 1,729,674
2015-02-05 13G TRIV / TriVascular Technologies, Inc. 1,814,061
2015-02-05 13G/A EPZM / Epizyme Inc 2,413,819
2014-02-13 13G CNAT / Conatus Pharmaceuticals Inc. 1,224,300
2014-02-12 13G EPZM / Epizyme Inc 2,880,485
2013-03-21 13D/A PCRX / Pacira BioSciences, Inc. 1,420,406